Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00284258
Status:
COMPLETED
Last Update Posted:
2012-11-02
First Post:
2006-01-30
Brief Title:
Phase IIIII Trial of CPT-115-FUl-LV Versus CPT-11TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer
Sponsor:
Taiho Pharmaceutical Co Ltd
Organization:
Taiho Pharmaceutical Co Ltd
Study Overview
Official Title:
Phase IIIII Trial of CPT-115-FUl-LV FOLFIRI Versus CPT-11TS-1 IRIS as Second Line Chemotherapy of Unresectable Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2012-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed as Phase IIIII Phase II is aimed to evaluate safety and efficacy of IRIS and feasibility of FOLFIRI Phase III is aimed to verify inferiority of the progression free survival of IRIS in comparison with FOLFIRI
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None